Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Risk Management in QMS in 2026: ICH Q9 Framework, GMP Controls, and CAPA Integration

Discover how pharmaceutical companies use ICH Q9 principles, GMP risk assessment, and CAPA integration to strengthen quality oversight, improve inspection readiness, and build effective quality risk management programs that support compliance, patient safety, and continuous improvement in 2026.
  • Blog, Quality Management System
Pharmaceutical quality professionals performing GMP risk assessment and quality risk assessment activities using the ICH Q9 risk management framework

Risk-Based Approach in GMP Inspection Compliance in 2026

Inspection findings in GMP environments increasingly stem from weak risk evaluation rather than missing procedures. This article explores GMP risk classification, pharmaceutical risk assessment, CAPA management, and audit readiness strategies that strengthen compliance and inspection performance across operations.
  • Blog, Quality Management System
Diagram showing GMP risk classification and pharmaceutical risk assessment workflow, including risk identification, evaluation, CAPA management, and audit readiness within a risk-based quality system.